基于SARS-CoV-2和流感快速抗原检测、等待RT-PCR结果的医院隔离策略:一项前瞻性观察研究
这项前瞻性观察研究纳入2022年10月31日至2023年3月31日两家医院急诊科1740例流感样症状成人患者,评估SARS-CoV-2/流感联合快速抗原检测(SIRAT)与RT-PCR相比的临床性能,并评价基于SIRAT等待RT-PCR结果的医院隔离策略。SIRAT对SARS-CoV-2灵敏度67.7%、特异度99.4%,对流感A/B灵敏度52.7%、特异度99.1%;未发现因SIRAT假阴性延迟隔离导致的症状性医院内SARS-CoV-2或流感传播,并节省了不必要的飞沫和接触隔离时间。
要点
- SIRAT对SARS-CoV-2灵敏度67.7%、特异度99.4%,对流感A/B灵敏度52.7%、特异度99.1%。
- 基于SIRAT等待RT-PCR结果的隔离策略未导致症状性医院内SARS-CoV-2或流感传播。
- 该策略共节省8712小时不必要的飞沫和接触隔离,每例中位节省最多6小时59分钟。
核心结论
- 对于急诊科就诊患者,基于SIRAT等待RT-PCR结果的医院隔离策略可节省不必要的隔离时间,且未导致SARS-CoV-2或流感病毒出现显著的症状性医院内传播。
研究设计与样本
- 前瞻性观察研究,纳入2022年10月31日至2023年3月31日两家医院急诊科所有出现流感样症状的成人患者,共1740例,其中1296例住院。
- 对上呼吸道样本同时进行SIRAT和SARS-CoV-2及流感RT-PCR检测,并将SIRAT结果与RT-PCR进行比较。
- 根据SIRAT结果在等待RT-PCR期间实施飞沫和接触隔离措施(DCIM),监测因SIRAT假阴性患者延迟隔离可能导致的症状性医院内SARS-CoV-2和流感感染,并计算节省的不必要DCIM小时数。
主要发现
- SARS-CoV-2和流感A/B的患病率分别为12.7%(221/1740)和9.9%(171/1740)。
- SIRAT对SARS-CoV-2的灵敏度为67.7%(95% CI 61.1-73.9%)(149/220),特异度为99.4%(95% CI 99.0-99.8%)(1510/1518)。
- SIRAT对流感A/B的灵敏度为52.7%(95% CI 44.9-60.4%)(89/169),特异度为99.1%(95% CI 98.5-99.5%)(1530/1544)。
- SARS-CoV-2的医院内传播风险为0%(95% CI 0-8.8%),流感为0%(95% CI 0-10%)。
- 共节省8712小时不必要的DCIM,每例患者中位节省最多6小时59分钟(IQR 11小时03分钟)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the clinical performance of a combined SARS-CoV-2/influenza rapid antigen test (SIRAT) and to evaluate a SIRAT-based hospital isolation policy awaiting RT-PCR results for patients presenting at the emergency department (ED). METHODS: We performed a prospective observational study including all adult patients presenting with influenza-like symptoms at the ED of two hospitals from 31 October 2022 to 31 March 2023. A SIRAT and SARS-CoV-2 and influenza RT-PCR were performed on upper respiratory samples. SIRAT results were compared with RT-PCR. Droplet and contact isolation measures (DCIM) were imposed based on SIRAT results awaiting RT-PCR. We monitored symptomatic nosocomial SARS-CoV-2 and influenza infections potentially caused by delayed isolation of patients with false negative SIRAT and the hours of unnecessary DCIM saved. RESULTS: We included 1740 patients of whom 1296 were hospitalized. SARS-CoV-2 and influenza A/B prevalence were 12.7% (221/1740) and 9.9% (171/1740). Sensitivity and specificity of the SIRAT were 67.7% (95% CI 61.1-73.9%) (149/220) and 99.4% (95% CI 99.0-99.8%) (1510/1518) for SARS-CoV-2 and 52.7% (95% CI 44.9-60.4%) (89/169) and 99.1% (95% CI 98.5-99.5%) (1530/1544) for influenza A/B. We found a 0% nosocomial transmission risk for SARS-CoV-2 (95% CI 0-8.8%) and influenza (95% CI 0-10%). In all, 8712 hours in total or a median up to 6 hours 59 minutes (IQR (interquartile range) 11h03) per patient of unnecessary DCIM were saved. DISCUSSION: A SIRAT-guided hospital isolation policy awaiting RT-PCR results for patients who present at the ED can save unnecessary isolation hours without having to lead to significant symptomatic nosocomial transmission of SARS-CoV-2 or influenza viruses.
引用
- Van der Moeren N, Zwart VF, Louise van Leest M, et al. A SARS-CoV-2 and influenza rapid antigen test-based hospital isolation policy awaiting RT-PCR, a prospective observational study. Clin Microbiol Infect. 2023. PMID: 37739262. doi:10.1016/j.cmi.2023.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。